Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Marseille,
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Marseille,
Click here to add this to my saved trials
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
A Pilot Trial of a CEA-TRICOM Based Vaccine and Radiation to Liver Metastasis in Adults With CEA Positive Solid Tumors
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
A Pilot Trial of a CEA-TRICOM Based Vaccine and Radiation to Liver Metastasis in Adults With CEA Positive Solid Tumors
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated:  9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated: 9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Liver Cancer
Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Liver Cancer
Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms
Status: Enrolling
Updated:  10/1/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms
Status: Enrolling
Updated: 10/1/2015
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated:  10/6/2015
Orlando Health
mi
from
Orlando, FL
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated: 10/6/2015
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated:  10/6/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS
Status: Enrolling
Updated: 10/6/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib
Status: Enrolling
Updated:  10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib
Status: Enrolling
Updated: 10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib
Status: Enrolling
Updated:  10/6/2015
National Cancer Center Hospital East
mi
from
Kashiwa,
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib
Status: Enrolling
Updated: 10/6/2015
National Cancer Center Hospital East
mi
from
Kashiwa,
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Investigational Drug Service
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Investigational Drug Service
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Clinica Viedma
mi
from
Viedma,
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Clinica Viedma
mi
from
Viedma,
Click here to add this to my saved trials
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
A Quality of Life Study for Patients With Primary or Metastatic Liver Cancer Who Are Treated With Radioembolization (Y90 Microspheres) or Transcatheter Arterial Embolization (TACE)
Status: Enrolling
Updated:  10/14/2015
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
A Quality of Life Study for Patients With Primary or Metastatic Liver Cancer Who Are Treated With Radioembolization (Y90 Microspheres) or Transcatheter Arterial Embolization (TACE)
Status: Enrolling
Updated: 10/14/2015
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  10/14/2015
California Pacific Medical Center
mi
from
San Francisco, CA
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 10/14/2015
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  10/14/2015
Columbia University, New York - Presbyterian Hospital
mi
from
New York, NY
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 10/14/2015
Columbia University, New York - Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  10/14/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 10/14/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  10/14/2015
UVA Cancer Center
mi
from
Charlottesville, VA
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 10/14/2015
UVA Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  10/14/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 10/14/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  10/14/2015
Tennessee Oncology, PLLCat Sarah Cannon Cancer Center
mi
from
Nashville, TN
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 10/14/2015
Tennessee Oncology, PLLCat Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
MR Techniques in the Evaluation of Hepatocellular Carcinoma: Gadoxetate
Status: Enrolling
Updated:  10/14/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
MR Techniques in the Evaluation of Hepatocellular Carcinoma: Gadoxetate
Status: Enrolling
Updated: 10/14/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer
Status: Enrolling
Updated:  10/22/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer
Status: Enrolling
Updated: 10/22/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors
Status: Enrolling
Updated:  10/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors
Status: Enrolling
Updated: 10/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Liver Cancer
A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Liver Cancer
A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
Yale Cancer Center
mi
from
New Haven, CT
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
VA Medical Center West Haven
mi
from
West Haven, CT
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
VA Medical Center West Haven
mi
from
West Haven, CT
Click here to add this to my saved trials
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
Brigham and Women's
mi
from
Boston, MA
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
Brigham and Women's
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
New York University Langone Medical Center
mi
from
New York, NY
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated:  11/3/2015
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Pilot Study of Effect of Sorafenib on Portal Pressure
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status: Enrolling
Updated: 11/3/2015
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
Lahey Hospital & Medical Center
mi
from
Burlington, CA
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
Lahey Hospital & Medical Center
mi
from
Burlington, CA
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
Rocky Mountain Cancer Centers
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
University of Miami Hospital and Clinics
mi
from
Miami, FL
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
University of Miami Hospital and Clinics
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
Ohio State University, Martha Morehouse Medical Plaza
mi
from
Columbus, OH
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
Ohio State University, Martha Morehouse Medical Plaza
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/3/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/3/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol
Status: Enrolling
Updated:  11/4/2015
City of Hope Medical Center
mi
from
Duarte, CA
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol
Status: Enrolling
Updated: 11/4/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver
Status: Enrolling
Updated:  11/9/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver
Status: Enrolling
Updated: 11/9/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials